Recent Investment Analysts’ Ratings Changes for Opus Genetics (IRD)

Posted by on May 15th, 2026

Opus Genetics (NASDAQ: IRD) recently received a number of ratings updates from brokerages and research firms:

  • 5/13/2026 – Opus Genetics had its price target lowered by Citizens Jmp from $12.00 to $11.00. They now have a “market outperform” rating on the stock.
  • 5/12/2026 – Opus Genetics was downgraded by Zacks Research from “hold” to “strong sell”.
  • 4/30/2026 – Opus Genetics had its “buy” rating reaffirmed by B. Riley Financial, Inc..
  • 4/28/2026 – Opus Genetics is now covered by Citigroup Inc.. They set an “outperform” rating on the stock.
  • 4/28/2026 – Opus Genetics is now covered by Citizens Jmp. They set a “market perform” rating and a $12.00 price target on the stock.
  • 4/21/2026 – Opus Genetics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 3/30/2026 – Opus Genetics is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $15.00 price target on the stock.
  • 3/16/2026 – Opus Genetics is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $10.00 price target on the stock.

Insider Activity

In other news, President Benjamin R. Yerxa sold 7,470 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $5.24, for a total value of $39,142.80. Following the sale, the president directly owned 711,535 shares in the company, valued at approximately $3,728,443.40. This trade represents a 1.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Ashwath Jayagopal sold 7,542 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $5.19, for a total transaction of $39,142.98. Following the completion of the sale, the insider owned 509,233 shares in the company, valued at approximately $2,642,919.27. The trade was a 1.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 73,395 shares of company stock valued at $382,278. Corporate insiders own 11.70% of the company’s stock.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

Featured Stories

Receive News & Ratings for Opus Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.